These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30345693)

  • 21. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size in cluster-randomized trials with time to event as the primary endpoint.
    Jahn-Eimermacher A; Ingel K; Schneider A
    Stat Med; 2013 Feb; 32(5):739-51. PubMed ID: 22865817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.
    Wang G; Cutter GR; Cofield SS; Lublin F; Wolinsky JS; Gustafson T; Krieger S; Salter A
    Mult Scler; 2017 Jun; 23(7):982-987. PubMed ID: 27682227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates.
    Zimmermann G; Kieser M; Bathke AC
    J Biopharm Stat; 2020; 30(1):143-159. PubMed ID: 31327284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
    Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
    J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the analysis of composite measures of quality in medical research.
    Moineddin R; Meaney C; Grunfeld E
    Stat Methods Med Res; 2017 Apr; 26(2):633-660. PubMed ID: 25296866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
    Xu R; Mehrotra DV; Shaw PA
    Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
    Waleed M; He J; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Meinl I; Havla J; Hohlfeld R; Kümpfel T
    Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
    Turkoz I; Sobel M; Alphs L
    Pharm Stat; 2019 Jan; 18(1):22-38. PubMed ID: 30221459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model.
    Altman RM; Petkau AJ; Vrecko D; Smith A
    Mult Scler; 2012 Nov; 18(11):1600-8. PubMed ID: 22495948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends.
    Asendorf T; Henderson R; Schmidli H; Friede T
    Stat Med; 2019 Apr; 38(9):1503-1528. PubMed ID: 30575061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.